€ 2 million for European Lyme Borreliosis innovation
The European Union has granted almost € 2 million to an international consortium that will bring a novel Lyme Borreliosis test to market. The project is led by Innatoss Laboratories from the Netherlands, and combines knowledge from Austria, Germany and the Netherlands. The team will finalize a break-through innovation for Lyme Borreliosis, making early diagnosis and timely treatment possible.
In total € 1.9 million have been granted to the ID-LYME project by the Horizon 2020 Fast Track to Innovation scheme, a part of the EU research and innovation program. The full consortium consists of the Medical University of Vienna (AU), DIARECT AG (DE), npk design and Innatoss Laboratories (NL). The ID-Lyme project is based on a proof of concept study and pre-clinical work performed by Innatoss. Their technology exploits the biomarker production of T cells to detect Lyme Borreliosis as early and distinct as possible.